Kosmidis Chris, Powell Georgina, Borrow Ray, Morris Julie, Alachkar Hana, Denning David W
The National Aspergillosis Centre, University Hospital of South Manchester, The University of Manchester, Manchester Academic Health Science Centre, Southmoor Road, M23 9LT Manchester, UK.
The National Aspergillosis Centre, University Hospital of South Manchester, The University of Manchester, Manchester Academic Health Science Centre, Southmoor Road, M23 9LT Manchester, UK.
Vaccine. 2015 Dec 16;33(51):7271-7275. doi: 10.1016/j.vaccine.2015.10.114. Epub 2015 Nov 3.
Pneumococcal infection causes significant morbidity in patients with underlying lung disease, and vaccination has been associated with reduced disease rates. Response to vaccination has not been studied in chronic lung conditions characterised by ongoing infection or inflammation like chronic pulmonary aspergillosis (CPA).
In a prospective observational study, consecutive patients with CPA, allergic aspergillosis and bronchiectasis attending a national referral centre received pneumococcal 23-valent polysaccharide vaccine (PPV-23) and had pre- and post-vaccination antibody concentrations quantified as part of routine clinical care. Serotype-specific pneumococcal IgG antibodies were quantified for 12 serotypes using a multiplex microsphere assay. A protective response was defined as a level of >1.3μg/mL or a ≥ fourfold rise in concentration for ≥70% of serotypes, pre to post-vaccination. C-reactive protein, Immunoglobulins and mannose binding lectin (MBL) levels were measured and correlated to vaccine response.
A total of 318 patients were enrolled. In vaccine-naïve patients (n=127), the lowest pre-vaccination levels were seen with serotypes 1 and 4 and the highest with serotype 19A. A protective response post-vaccination was seen in 50% of patients. The poorest responses were observed with serotypes 1, 3 and 4. Levels of C-reactive protein did not affect efficacy. Profound MBL deficiency was found in 28.8%; there were no significant differences in response to vaccination in patients with or without MBL deficiency. Post-vaccination serotype-specific concentrations waned gradually, however they were still elevated compared to pre-vaccination after 2-5 years.
Patients with chronic and allergic aspergillosis exhibited a poor response to PPV-23 vaccination compared to healthy adults. An alternative vaccination strategy or delay of vaccination until their underlying condition is better controlled, e.g. after treatment with antifungals may result in better response.
肺炎球菌感染在患有基础肺部疾病的患者中会导致显著的发病率,接种疫苗与疾病发生率降低有关。对于像慢性肺曲霉病(CPA)这种以持续感染或炎症为特征的慢性肺部疾病,尚未对疫苗接种反应进行研究。
在一项前瞻性观察性研究中,连续就诊于一家国家转诊中心的CPA、变应性曲霉病和支气管扩张症患者接受了肺炎球菌23价多糖疫苗(PPV - 23)接种,并在常规临床护理中对接种前后的抗体浓度进行了定量。使用多重微球分析法对12种血清型的血清型特异性肺炎球菌IgG抗体进行了定量。保护性反应被定义为接种后≥70%的血清型浓度>1.3μg/mL或浓度升高≥四倍。测量了C反应蛋白、免疫球蛋白和甘露糖结合凝集素(MBL)水平,并将其与疫苗反应相关联。
共纳入318例患者。在未接种过疫苗的患者(n = 127)中,血清型1和4的接种前水平最低,血清型19A的最高。50%的患者接种后出现了保护性反应。血清型1、3和4的反应最差。C反应蛋白水平不影响疗效。28.8%的患者存在严重MBL缺乏;有无MBL缺乏的患者在疫苗接种反应方面无显著差异。接种后血清型特异性浓度逐渐下降,然而2 - 5年后与接种前相比仍有所升高。
与健康成年人相比,慢性和变应性曲霉病患者对PPV - 23疫苗接种的反应较差。替代的疫苗接种策略或在其基础疾病得到更好控制之前推迟接种,例如在抗真菌治疗后,可能会产生更好的反应。